LOS ANGELES, CA — Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that its CEO and Chairman, John Yu, MD, will deliver a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled to take place from September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.
This presentation represents a significant opportunity for Kairos Pharma to showcase its innovative approach to oncology therapeutics to a broad audience of institutional investors, analysts, and industry peers. The company is leveraging structural biology to address two major challenges in cancer treatment: drug resistance and immune suppression. By targeting these mechanisms, Kairos aims to enhance the efficacy of existing therapies and improve patient outcomes.
At the heart of Kairos Pharma's pipeline is its lead candidate, ENV-105, a monoclonal antibody designed to target CD105, a protein that has been identified as a key driver of resistance and disease relapse in response to standard cancer treatments. ENV-105 is intended to reverse drug resistance by binding to CD105 and restoring the effectiveness of standard therapies across multiple cancer types. This novel mechanism could potentially fill a critical unmet need in oncology, where resistance to chemotherapy, targeted therapy, and immunotherapy remains a major hurdle.
The company's participation in the H.C. Wainwright conference is particularly timely, as the biopharmaceutical sector continues to see heightened interest in innovative approaches to cancer treatment. Investors are increasingly focused on companies with differentiated science and clear clinical development plans. Kairos Pharma's presentation will likely highlight recent progress, upcoming milestones, and the strategic vision for advancing ENV-105 through clinical trials.
The conference, one of the most anticipated events in the investment community, brings together leading public and private companies in the healthcare sector. For Kairos Pharma, this platform offers a chance to increase visibility among potential partners and investors, which could be instrumental in supporting future research and development efforts.
Kairos Pharma, headquartered in Los Angeles, California, is dedicated to improving cancer care through precision medicine. The company's focus on CD105 as a therapeutic target is supported by research suggesting that CD105 is not only a marker of angiogenesis but also plays a role in tumor progression and resistance. By inhibiting CD105, ENV-105 may not only sensitize tumors to existing drugs but also modulate the tumor microenvironment to enhance immune responses.
The announcement of the CEO's presentation underscores the company's commitment to transparency and engagement with the investment community. As Kairos Pharma continues to advance its clinical programs, the insights shared at the conference could provide valuable information on the company's strategy and the potential impact of its lead candidate.
For more details about the conference and Kairos Pharma's participation, interested parties can view the full press release at https://ibn.fm/NrBQD. Additionally, the latest news and updates regarding the company are available in its newsroom at https://ibn.fm/KAPA.
Kairos Pharma's presence at the H.C. Wainwright conference signals its emergence as a notable player in the oncology space, with a promising therapeutic approach that could address a significant challenge in cancer treatment. The company's progress will be closely watched by investors and clinicians alike as it moves forward.
